The physico-chemical landscape of extracellular vesicles
Source abstract
Abstract
Extracellular vesicles are defined as nanosized to microsized particles, delimited by a lipid bilayer membrane, that seem to be released by all cell types and that can transport bioactive molecules between cells, tissues, organs and organisms. Therefore, extracellular vesicles are being explored as biomaterials, drug delivery nanocarriers, therapeutics and multiplexed biomarkers. However, the isolation, characterization and large-scale manufacturing of extracellular vesicles remains challenging. In this Review, we delineate the landscape of the physico-chemical properties of extracellular vesicles, originating from their composition and conformational ensemble, and outline how this landscape is defined by the heterogeneity of their size, composition, membrane structure, surface interactions, cargo and co-isolates. We explore the implications of this heterogeneity on the definition of the purity, identity and function of extracellular vesicles. The comparison of this landscape with the landscape of antibody therapeutics and viral vectors can identify lessons to be learned from the bioprocessing of these products, and the distinct challenges associated with the manufacturing and isolation of extracellular vesicles from biofluids, which will require new concepts and technologies. We highlight the importance of a thorough understanding of the physico-chemical properties of extracellular vesicles for their clinical translation. This includes the development of bioprocessing approaches, assignment of product quality attributes, consistency of extracellular vesicle products and manufacturing at scale.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Extracellular vesicles in disease · Nanopore and Nanochannel Transport Studies · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Mullard, A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 20, 491–495 (2021).10.1038/d41573-021-00079-7 ↗
2. Damase, T. R. et al. The limitless future of RNA therapeutics. Front. Bioeng. Biotechnol. 9, 628137 (2021).10.3389/fbioe.2021.628137 ↗
3. Karikó, K. In vitro-transcribed mRNA therapeutics: out of the shadows and into the spotlight. Mol. Ther. 27, 691–692 (2019).10.1016/j.ymthe.2019.03.009 ↗
4. Sun, D. X., Gao, W., Hu, H. X. & Zhou, S. M. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B 12, 3049–3062 (2022).10.1016/j.apsb.2022.02.002 ↗
5. Picanco-Castro, V. et al. Emerging patent landscape for non-viral vectors used for gene therapy. Nat. Biotechnol. 38, 151–158 (2020).10.1038/s41587-019-0402-x ↗
6. Mitchell, M. J. et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20, 101–124 (2021).10.1038/s41573-020-0090-8 ↗
7. Zhao, Z. M., Anselmo, A. C. & Mitragotri, S. Viral vector-based gene therapies in the clinic. Bioeng. Transl. Med. 7, e10258 (2022).10.1002/btm2.10258 ↗
8. Welsh, J. A. et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J. Extracell. Vesicles 13, e12404 (2024).10.1002/jev2.12404 ↗
9. Wauben, M. H. M. in Extracellular Vesicles 2nd edn, 378–389 (Academic, 2023).10.1016/B978-0-12-821618-7.00230-3 ↗
10. Elsharkasy, O. M. et al. Extracellular vesicles as drug delivery systems: why and how? Adv. Drug Deliv. Rev. 159, 332–343 (2020).10.1016/j.addr.2020.04.004 ↗
11. Witwer, K. W. & Wolfram, J. Extracellular vesicles versus synthetic nanoparticles for drug delivery. Nat. Rev. Mater. 6, 103–106 (2021).10.1038/s41578-020-00277-6 ↗
12. Cheng, L. S. & Hill, A. F. Therapeutically harnessing extracellular vesicles. Nat. Rev. Drug Discov. 21, 379–399 (2022).10.1038/s41573-022-00410-w ↗
13. Gupta, D. et al. Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. Nat. Biomed. Eng. 5, 1084–1098 (2021).10.1038/s41551-021-00792-z ↗
14. Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748–759 (2021).10.1038/s41565-021-00931-2 ↗
15. Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367, eaau6977 (2020).10.1126/science.aau6977 ↗
16. Moller, A. & Lobb, R. J. The evolving translational potential of small extracellular vesicles in cancer. Nat. Rev. Cancer 20, 697–709 (2020).10.1038/s41568-020-00299-w ↗
17. van Dommelen, S. M. et al. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J. Control. Rel. 161, 635–644 (2012).10.1016/j.jconrel.2011.11.021 ↗
18. Semchenko, E. A., Tan, A., Borrow, R. & Seib, K. L. The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae. Clin. Infect. Dis. 69, 1101–1111 (2019).10.1093/cid/ciy1061 ↗
19. Shi, M. M. et al. Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. J. Extracell. Vesicles 10, e12134 (2021).10.1002/jev2.12134 ↗
20. Lotfy, A., AboQuella, N. M. & Wang, H. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res. Ther. 14, 66 (2023).10.1186/s13287-023-03287-7 ↗
21. Zarrabi, M. et al. Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial. Stem Cell Res. Ther. 14, 169 (2023).10.1186/s13287-023-03402-8 ↗
22. de Castilla, P. E. M. et al. Extracellular vesicles as a drug delivery system: a systematic review of preclinical studies. Adv. Drug Deliv. Rev. 175, 113801 (2021).10.1016/j.addr.2021.05.011 ↗
23. Duong, A., Parmar, G., Kirkham, A. M., Burger, D. & Allan, D. S. Registered clinical trials investigating treatment with cell-derived extracellular vesicles: a scoping review. Cytotherapy 25, 939–945 (2023).10.1016/j.jcyt.2023.04.007 ↗
24. Chi, E. Y., Krishnan, S., Randolph, T. W. & Carpenter, J. F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 20, 1325–1336 (2003).10.1023/A:1025771421906 ↗
25. Ausserwöger, H. et al. Non-specificity as the sticky problem in therapeutic antibody development. Nat. Rev. Chem. 6, 844–861 (2022).10.1038/s41570-022-00438-x ↗
26. Xu, Y. D. et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs 11, 239–264 (2019).10.1080/19420862.2018.1553476 ↗
27. Srivastava, A., Mallela, K. M. G., Deorkar, N. & Brophy, G. Manufacturing challenges and rational formulation development for AAV viral vectors. J. Pharm. Sci. 110, 2609–2624 (2021).10.1016/j.xphs.2021.03.024 ↗
28. Li, C. W. & Samulski, R. J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 21, 255–272 (2020).
29. Wang, D., Tai, P. W. L. & Gao, G. P. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358–378 (2019).10.1038/s41573-019-0012-9 ↗
30. Worner, T. P. et al. Adeno-associated virus capsid assembly is divergent and stochastic. Nat. Commun. 12, 1642 (2021).10.1038/s41467-021-21935-5 ↗
31. Kumru, O. S. et al. Physical characterization and stabilization of a lentiviral vector against adsorption and freeze–thaw. J. Pharm. Sci. 107, 2764–2774 (2018).10.1016/j.xphs.2018.07.010 ↗
32. Samulski, R. J. & Muzyczka, N. AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451 (2014).10.1146/annurev-virology-031413-085355 ↗
33. Buzás, E. I., Tóth, E., Sódar, B. W. & Szabó-Taylor, K. Molecular interactions at the surface of extracellular vesicles. Semin. Immunopathol. 40, 453–464 (2018). This article extends the concept of the biomolecular corona to extracellular vesicles.10.1007/s00281-018-0682-0 ↗
34. Cedervall, T. et al. Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104, 2050–2055 (2007).10.1073/pnas.0608582104 ↗
35. Mahmoudi, M., Landry, M. P., Moore, A. & Coreas, R. The protein corona from nanomedicine to environmental science. Nat. Rev. Mater. 8, 422–438 (2023).10.1038/s41578-023-00552-2 ↗
36. Dobson, C. M. Protein folding and misfolding. Nature 426, 884–890 (2003).10.1038/nature02261 ↗
37. Dobson, C. M. Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol. 15, 3–16 (2004).10.1016/j.semcdb.2003.12.008 ↗
38. Hartl, F. U. & Hayer-Hartl, M. Converging concepts of protein folding in vitro and in vivo. Nat. Struct. Mol. Biol. 16, 574–581 (2009).10.1038/nsmb.1591 ↗
39. Nikoloff, J. M., Saucedo-Espinosa, M. A., Kling, A. & Dittrich, P. S. Identifying extracellular vesicle populations from single cells. Proc. Natl Acad. Sci. USA 118, e2106630118 (2021). This article demonstrates the continuum of vesicle structures released by single cells.10.1073/pnas.2106630118 ↗
40. Nolte-‘t Hoen, E., Cremer, T., Gallo, R. C. & Margolis, L. B. Extracellular vesicles and viruses: are they close relatives? Proc. Natl Acad. Sci. USA 113, 9155–9161 (2016). This article discusses how biological particles with partially overlapping energies and physico-chemical properties can have substantially different biological functions.10.1073/pnas.1605146113 ↗
41. Fuxreiter, M. Fuzziness in protein interactions — a historical perspective. J. Mol. Biol. 430, 2278–2287 (2018).10.1016/j.jmb.2018.02.015 ↗
42. Gianni, S. et al. Fuzziness and frustration in the energy landscape of protein folding, function, and assembly. Acc. Chem. Res. 54, 1251–1259 (2021).10.1021/acs.accounts.0c00813 ↗
43. Busatto, S. et al. The nanostructured secretome. Biomater. Sci. 8, 39–63 (2019). This article describes extracellular nanoparticles and their traits in a concise framework, including their biogenesis, colloidal properties, engineering and clinical translation.10.1039/C9BM01007F ↗
44. Buzas, E. I. Opportunities and challenges in studying the extracellular vesicle corona. Nat. Cell Biol. 24, 1322–1325 (2022).10.1038/s41556-022-00983-z ↗
45. Toth, E. A. et al. Formation of a protein corona on the surface of extracellular vesicles in blood plasma. J. Extracell. Vesicles 10, e12140 (2021).10.1002/jev2.12140 ↗
46. Wolf, M. et al. A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulation. J. Extracell. Vesicles 11, e12207 (2022).10.1002/jev2.12207 ↗
47. Busatto, S. et al. Considerations for extracellular vesicle and lipoprotein interactions in cell culture assays. J. Extracell. Vesicles 11, e12202 (2022).10.1002/jev2.12202 ↗
48. Busatto, S. et al. Brain metastases-derived extracellular vesicles induce binding and aggregation of low-density lipoprotein. J. Nanobiotechnol. 18, 162 (2020).10.1186/s12951-020-00722-2 ↗
49. Lozano-Andrés, E. et al. Physical association of low density lipoprotein particles and extracellular vesicles unveiled by single particle analysis. J. Extracell. Vesicles 12, e12376 (2023).10.1002/jev2.12376 ↗
50. Musicò, A. et al. Surface functionalization of extracellular vesicle nanoparticles with antibodies: a first study on the protein corona ‘variable’. Nanoscale Adv. 5, 4703–4717 (2023).10.1039/D3NA00280B ↗
51. Radeghieri, A. A. et al. Active antithrombin glycoforms are selectively physisorbed on plasma extracellular vesicles. J. Extracell. Biol. 1, e57 (2022).10.1002/jex2.57 ↗
52. Ridolfi, A. et al. Particle profiling of EV–lipoprotein mixtures by AFM nanomechanical imaging. J. Extracell. Vesicles 12, e12349 (2023).10.1002/jev2.12349 ↗
53. Dietz, L. et al. Uptake of extracellular vesicles into immune cells is enhanced by the protein corona. J. Extracell. Vesicles 12, e12399 (2023).10.1002/jev2.12399 ↗
54. Liam-Or, R. et al. Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent. Nat. Nanotechnol. 19, 846–855 (2024).10.1038/s41565-023-01585-y ↗
55. Perez-Hernandez, D. et al. The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes. J. Biol. Chem. 288, 11649–11661 (2013).10.1074/jbc.M112.445304 ↗
56. Thuma, F., Heiler, S., Schnölzer, M. & Zöller, M. Palmitoylated claudin7 captured in glycolipid-enriched membrane microdomains promotes metastasis via associated transmembrane and cytosolic molecules. Oncotarget 7, 30659–30677 (2016).10.18632/oncotarget.8928 ↗
57. Yang, W., Di Vizio, D., Kirchner, M., Steen, H. & Freeman, M. R. Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. Mol. Cell Proteom. 9, 54–70 (2010).10.1074/mcp.M800448-MCP200 ↗
58. Romancino, D. P. et al. Palmitoylation is a post-translational modification of Alix regulating the membrane organization of exosome-like small extracellular vesicles. Biochim. Biophys. Acta Gen. Subj. 1862, 2879–2887 (2018).10.1016/j.bbagen.2018.09.004 ↗
59. Subra, C., Laulagnier, K., Perret, B. & Record, M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 89, 205–212 (2007).10.1016/j.biochi.2006.10.014 ↗
60. Witwer, K. W. et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2, e20360 (2013).10.3402/jev.v2i0.20360 ↗
61. Buzas, E. I. The roles of extracellular vesicles in the immune system. Nat. Rev. Immunol. 23, 236–250 (2023).10.1038/s41577-022-00763-8 ↗
62. Thery, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (2018).10.1080/20013078.2018.1535750 ↗
63. Cvjetkovic, A., Lötvall, J. & Lässer, C. The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles. J. Extracell. Vesicles 3, e2311 (2014).10.3402/jev.v3.23111 ↗
64. Maiolo, D. et al. Colorimetric nanoplasmonic assay to determine purity and titrate extracellular vesicles. Anal. Chem. 87, 4168–4176 (2015).10.1021/ac504861d ↗
65. Osteikoetxea, X. et al. Improved characterization of EV preparations based on protein to lipid ratio and lipid properties. PLoS ONE 10, e0121184 (2015).10.1371/journal.pone.0121184 ↗
66. Webber, J. & Clayton, A. How pure are your vesicles? J. Extracell. Vesicles 2, e19861 (2013).10.3402/jev.v2i0.19861 ↗
67. Ridolfi, A. et al. AFM-based high-throughput nanomechanical screening of single extracellular vesicles. Anal. Chem. 92, 10274–10282 (2020).10.1021/acs.analchem.9b05716 ↗
68. LeClaire, M., Gimzewski, J. & Sharma, S. A review of the biomechanical properties of single extracellular vesicles. Nano Select 2, 1–15 (2021).10.1002/nano.202000129 ↗
69. Vorselen, D. et al. The fluid membrane determines mechanics of erythrocyte extracellular vesicles and is softened in hereditary spherocytosis. Nat. Commun. 9, 4960 (2018).10.1038/s41467-018-07445-x ↗
70. Vorselen, D., Piontek, M. C., Roos, W. H. & Wuite, G. J. L. Mechanical characterization of liposomes and extracellular vesicles, a protocol. Front. Mol. Biosci. 7, 139 (2020).10.3389/fmolb.2020.00139 ↗
71. Kashkanova, A. D., Blessing, M., Gemeinhardt, A., Soulat, D. & Sandoghdar, V. Precision size and refractive index analysis of weakly scattering nanoparticles in polydispersions. Nat. Methods 19, 586–593 (2022).10.1038/s41592-022-01460-z ↗
72. Kashkanova, A. D. et al. Label-free discrimination of extracellular vesicles from large lipoproteins. J. Extracell. Vesicles 12, e12348 (2023).10.1002/jev2.12348 ↗
73. Zendrini, A. et al. Augmented COlorimetric NANoplasmonic (CONAN) method for grading purity and determine concentration of EV microliter volume solutions. Front. Bioeng. Biotechnol. 7, 452 (2019).10.3389/fbioe.2019.00452 ↗
74. Zendrini, A. et al. On the interaction and nanoplasmonics of gold nanoparticles and lipoproteins. JCIS Open 11, 100088 (2023).10.1016/j.jciso.2023.100088 ↗
75. Caselli, L. et al. A plasmon-based nanoruler to probe the mechanical properties of synthetic and biogenic nanosized lipid vesicles. Nanoscale Horiz. 6, 543–550 (2021).10.1039/D1NH00012H ↗
76. Mihály, J. et al. Characterization of extracellular vesicles by IR spectroscopy: fast and simple classification based on amide and C–H stretching vibrations. Biochim. Biophys. Acta Biomembr. 1859, 459–466 (2017).10.1016/j.bbamem.2016.12.005 ↗
77. Enciso-Martinez, A. et al. Synchronized Rayleigh and Raman scattering for the characterization of single optically trapped extracellular vesicles. Nanomedicine 24, 102109 (2020).10.1016/j.nano.2019.102109 ↗
78. Enciso-Martinez, A. et al. Label-free identification and chemical characterisation of single extracellular vesicles and lipoproteins by synchronous Rayleigh and Raman scattering. J. Extracell. Vesicles 9, 1730134 (2020).10.1080/20013078.2020.1730134 ↗
79. Gualerzi, A. et al. Raman spectroscopy as a quick tool to assess purity of extracellular vesicle preparations and predict their functionality. J. Extracell. Vesicles 8, 1568780 (2019).10.1080/20013078.2019.1568780 ↗
80. Zini, J. et al. Infrared and Raman spectroscopy for purity assessment of extracellular vesicles. Eur. J. Pharm. Sci. 172, 106135 (2022).10.1016/j.ejps.2022.106135 ↗
81. Margolis, L. & Sadovskyz, Y. The biology of extracellular vesicles: the known unknowns. PLoS Biol. 17, e3000363 (2019).10.1371/journal.pbio.3000363 ↗
82. Paolicelli, R. C., Bergamini, G. & Rajendran, L. Cell-to-cell communication by extracellular vesicles: focus on microglia. Neuroscience 405, 148–157 (2019).10.1016/j.neuroscience.2018.04.003 ↗
83. Teng, F. & Fussenegger, M. Shedding light on extracellular vesicle biogenesis and bioengineering. Adv. Sci. 8, 2003505 (2021).10.1002/advs.202003505 ↗
84. van Niel, G. et al. Challenges and directions in studying cell–cell communication by extracellular vesicles. Nat. Rev. Mol. Cell Biol. 23, 369–382 (2022).10.1038/s41580-022-00460-3 ↗
85. Van Delen, M., Derdelinckx, J., Wouters, K., Nelissen, I. & Cools, N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J. Extracell. Vesicles 13, e12458 (2024).10.1002/jev2.12458 ↗
86. Paolini, L. et al. Residual matrix from different separation techniques impacts exosome biological activity. Sci. Rep. 6, 23550 (2016).10.1038/srep23550 ↗
87. Adamo, G. et al. Nanoalgosomes: introducing extracellular vesicles produced by microalgae. J. Extracell. Vesicles 10, e12081 (2021).10.1002/jev2.12081 ↗
88. Paterna, A. et al. Isolation of extracellular vesicles from microalgae: a renewable and scalable bioprocess. Front. Bioeng. Biotechnol. 10, 836747 (2022).10.3389/fbioe.2022.836747 ↗
89. Trenkenschuh, E. et al. Enhancing the stabilization potential of lyophilization for extracellular vesicles. Adv. Healthc. Mater. 11, e2100538 (2022).10.1002/adhm.202100538 ↗
90. Jeyaram, A. & Jay, S. M. Preservation and storage stability of extracellular vesicles for therapeutic applications. AAPS J. 20, 1 (2017).10.1208/s12248-017-0160-y ↗
91. Fitzgerald, W. et al. A system of cytokines encapsulated in extracellular vesicles. Sci. Rep. 8, 8973 (2018).10.1038/s41598-018-27190-x ↗
92. O’Brien, K., Breyne, K., Ughetto, S., Laurent, L. C. & Breakefield, X. O. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat. Rev. Mol. Cell Biol. 21, 585–606 (2020).10.1038/s41580-020-0251-y ↗
93. Nieuwland, R., Enciso-Martinez, A. & Bracht, J. W. P. Clinical applications and challenges in the field of extracellular vesicles. Med. Genet. 35, 251–258 (2023).
94. Cao, H. et al. In vivo tracking of mesenchymal stem cell-derived extracellular vesicles improving mitochondrial function in renal ischemia-reperfusion injury. ACS Nano 14, 4014–4026 (2020).10.1021/acsnano.9b08207 ↗
95. Xia, Y., Zhang, J., Liu, G. & Wolfram, J. Immunogenicity of extracellular vesicles. Adv. Mater. 36, e2403199 (2024).10.1002/adma.202403199 ↗
96. Wiklander, O. P. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles 4, 26316 (2015).10.3402/jev.v4.26316 ↗
97. Smyth, T. et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J. Control. Rel. 199, 145–155 (2015).10.1016/j.jconrel.2014.12.013 ↗
98. Kang, M., Jordan, V., Blenkiron, C. & Chamley, L. W. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J. Extracell. Vesicles 10, e12085 (2021).10.1002/jev2.12085 ↗
99. Driedonks, T. et al. Pharmacokinetics and biodistribution of extracellular vesicles administered intravenously and intranasally to Macaca nemestrina. J. Extracell. Biol. 1, e59 (2022).10.1002/jex2.59 ↗
100. Parada, N., Romero-Trujillo, A., Georges, N. & Alcayaga-Miranda, F. Camouflage strategies for therapeutic exosomes evasion from phagocytosis. J. Adv. Res. 31, 61–74 (2021).10.1016/j.jare.2021.01.001 ↗